237 Putnam Ave
4 articles with Strand Therapeutics
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
Strand Therapeutics Awarded Phase I NIH SBIR Contract to Develop mRNA-based CAR-T Immunotherapy for Non-Hodgkin’s Lymphoma
Strand Therapeutics today announced that the company was awarded a Phase I Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI)
Today, Strand Therapeutics, announced Jake Becraft, PhD, co-founder and CEO of Strand, has been named to MIT Technology Review’s prestigious annual list of Innovators Under 35.
Strand Therapeutics today announced that the company raised $52 million in an oversubscribed Series A financing round.